Veracyte Stock Based Compensation Over Time

VCYT Stock  USD 41.18  0.19  0.46%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Veracyte Performance and Veracyte Correlation.
For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.
  
Stock Based Compensation is likely to gain to about 34.8 M in 2024. Stock Based Compensation To Revenue is likely to gain to 0.11 in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.13)
Revenue Per Share
5.644
Quarterly Revenue Growth
0.286
Return On Assets
0.0107
Return On Equity
(0.01)
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Stock Based Compensation Analysis

Compare Veracyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Stock Based Compensation Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
CRNX270 K270 K270 K270 K270 K270 K270 K271 K2.3 M6.3 M10.4 M17.4 M28.3 M40.9 M43 M
CYTK1.9 M3.1 M3.8 M3.6 M3.3 M4.6 M7.1 MM9.8 M10.8 M17.6 M26.8 M47.9 M72.1 M75.7 M
GPCR570 K570 K570 K570 K570 K570 K570 K570 K570 K570 K570 K1.5 M2.5 M8.2 M8.6 M
KURA7117117117117112.3 M2.1 M4.5 M8.7 M9.4 M12.8 M23.6 M26.3 M28.1 M29.5 M
PTGX42 K42 K42 K42 K42 K99 K2.1 M4.2 M6.9 M8.4 M7.9 M16.4 M24.2 M29.3 M30.8 M
MRUS251.3 K251.3 K251.3 K251.3 K188.5 K619.9 K3.5 M15.4 M9.1 M7.8 M9.4 M17.1 M24.5 M26.2 M27.5 M
REPL208 K208 K208 K208 K208 K208 K208 K812 K2.7 M7.7 M11.8 M24.3 M28.1 M34.1 M35.8 M
ENTA259 K424 K1.1 M2.7 M5.8 M9.4 M13.1 M15.8 M19.2 M19.6 M21 M27 M28.2 M26.8 M14 M
SNDX139 K139 K139 K1.4 M2.3 M3.9 M4.7 M5.5 M6.2 MM9.1 M13.3 M16 M31 M32.5 M
VTYX198 K198 K198 K198 K198 K198 K198 K198 K198 K198 K45 K2.7 M16.6 M28.6 M30 M
QURE1.2 M1.2 M2.3 M2.8 M11.5 M8.3 M6.2 M10.1 M10.7 M17.5 M21.8 M25.6 M34.2 M35.1 M36.8 M
RCKT486 K486 K486 K(148 K)177 K2.4 M2.9 MM13.6 M13.4 M18.6 M29.2 M31 M39.4 M41.4 M
RYTM298 K298 K298 K298 K298 K298 K1.2 M2.3 M6.4 M11.9 M17.5 M20.8 M19.8 M32.6 M34.2 M
SLDB764 K764 K764 K764 K764 K764 K1.5 M5.3 MM14.2 M11.6 M13.4 M7.5 M7.6 M8.3 M
MGTX2.8 M2.8 M2.8 M2.8 M2.8 M2.8 M2.8 MM17.9 M15.9 M18.4 M20.8 M28.6 M27.7 M18.6 M
IDYA136 K136 K136 K136 K136 K136 K136 K136 K950 K2.2 M3.6 M8.2 M11.6 M18.5 M19.4 M
ANAB151 K151 K151 K151 K160 K604 K1.2 M4.4 M10 M12.4 M11.5 M15.3 M27.4 M33.2 M34.9 M
KROS81 K81 K81 K81 K81 K81 K81 K81 K81 K59 K4.1 M11.7 M18.7 M28.8 M30.2 M

Veracyte and related stocks such as Crinetics Pharmaceuticals, Viridian Therapeutics, and Cytokinetics Stock Based Compensation description

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

My Equities

My Current Equities and Potential Positions

Veracyte
VCYT
ClassificationHealthcare
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 41.18

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.